Martina Pigazzi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4690579/publications.pdf

Version: 2024-02-01

331259 276539 76 1,848 21 41 h-index citations g-index papers 78 78 78 2866 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Results of the AIEOP AML 2002/01 multicenter prospective trial for the treatment of children with acute myeloid leukemia. Blood, 2013, 122, 170-178.	0.6	162
2	Pediatric non–Down syndrome acute megakaryoblastic leukemia is characterized by distinct genomic subsets with varying outcomes. Nature Genetics, 2017, 49, 451-456.	9.4	152
3	RNA-binding protein IGF2BP3 targeting of oncogenic transcripts promotes hematopoietic progenitor proliferation. Journal of Clinical Investigation, 2016, 126, 1495-1511.	3.9	128
4	miR-34b Targets Cyclic AMP–Responsive Element Binding Protein in Acute Myeloid Leukemia. Cancer Research, 2009, 69, 2471-2478.	0.4	127
5	CBFA2T3-GLIS2 fusion transcript is a novel common feature in pediatric, cytogenetically normal AML, not restricted to FAB M7 subtype. Blood, 2013, 121, 3469-3472.	0.6	119
6	The IncRNA CASC15 regulates SOX4 expression in RUNX1-rearranged acute leukemia. Molecular Cancer, 2017, 16, 126.	7.9	108
7	Drp1 Controls Effective T Cell Immune-Surveillance by Regulating T Cell Migration, Proliferation, and cMyc-Dependent Metabolic Reprogramming. Cell Reports, 2018, 25, 3059-3073.e10.	2.9	82
8	LncRNA Expression Discriminates Karyotype and Predicts Survival in B-Lymphoblastic Leukemia. Molecular Cancer Research, 2015, 13, 839-851.	1.5	81
9	Recurrent abnormalities can be used for risk group stratification in pediatric AMKL: a retrospective intergroup study. Blood, 2016, 127, 3424-3430.	0.6	79
10	Prognostic significance of flowâ€cytometry evaluation of minimal residual disease in children with acute myeloid leukaemia treated according to the <scp>AIEOP</scp> â€ <scp>AML</scp> 2002/01 study protocol. British Journal of Haematology, 2017, 177, 116-126.	1.2	54
11	cAMP response element binding protein (CREB) overexpression CREB has been described as critical for leukemia progression. Haematologica, 2007, 92, 1435-1437.	1.7	48
12	Prognostic impact of $t(16;21)(p11;q22)$ and $t(16;21)(q24;q22)$ in pediatric AML: a retrospective study by the I-BFM Study Group. Blood, 2018, 132, 1584-1592.	0.6	45
13	Sox4 cooperates with CREB in myeloid transformation. Blood, 2012, 120, 155-165.	0.6	43
14	MicroRNA-34b promoter hypermethylation induces CREB overexpression and contributes to myeloid transformation. Haematologica, 2013, 98, 602-610.	1.7	42
15	MLL-AF6 fusion oncogene sequesters AF6 into the nucleus to trigger RAS activation in myeloid leukemia. Blood, 2014, 124, 263-272.	0.6	41
16	Minimal residual disease monitored after induction therapy by RQ-PCR can contribute to tailor treatment of patients with t(8;21) RUNX1-RUNX1T1 rearrangement. Haematologica, 2015, 100, e99-e101.	1.7	35
17	BAG1: The Guardian of Anti-Apoptotic Proteins in Acute Myeloid Leukemia. PLoS ONE, 2011, 6, e26097.	1.1	35
18	Hh/Gli antagonist in acute myeloid leukemia with CBFA2T3-GLIS2 fusion gene. Journal of Hematology and Oncology, 2017, 10, 26.	6.9	34

#	Article	IF	CITATIONS
19	CREB: A Key Regulator of Normal and Neoplastic Hematopoiesis. Advances in Hematology, 2009, 2009, 1-8.	0.6	29
20	Infants with acute myeloid leukemia treated according to the Associazione Italiana di Ematologia e Oncologia Pediatrica 2002/01 protocol have an outcome comparable to that of older children. Haematologica, 2014, 99, e127-e129.	1.7	26
21	Targeting mesenchymal stromal cells plasticity to reroute acute myeloid leukemia course. Blood, 2021, 138, 557-570.	0.6	26
22	Genomic complexity and dynamics of clonal evolution in childhood acute myeloid leukemia studied with whole-exome sequencing. Oncotarget, 2016, 7, 56746-56757.	0.8	23
23	DHH-RHEBL1fusion transcript: a novel recurrent feature in the new landscape of pediatricCBFA2T3-GLIS2-positive acute myeloid leukemia. Oncotarget, 2013, 4, 1712-1720.	0.8	23
24	Label-free, real-time on-chip sensing of living cells via grating-coupled surface plasmon resonance. Biophysical Chemistry, 2019, 254, 106262.	1.5	21
25	Integrative Genomic Analysis of Pediatric Myeloid-Related Acute Leukemias Identifies Novel Subtypes and Prognostic Indicators. Blood Cancer Discovery, 2021, 2, 586-599.	2.6	21
26	ZNF521 sustains the differentiation block in MLL-rearranged acute myeloid leukemia. Oncotarget, 2017, 8, 26129-26141.	0.8	21
27	RSK inhibitor BI-D1870 inhibits acute myeloid leukemia cell proliferation by targeting mitotic exit. Oncotarget, 2020, 11, 2387-2403.	0.8	18
28	Epigenetic heterogeneity affects the risk of relapse in children with t(8;21)RUNX1-RUNX1T1-rearranged AML. Leukemia, 2018, 32, 1124-1134.	3.3	17
29	Presence of high-ERG expression is an independent unfavorable prognostic marker in MLL-rearranged childhood myeloid leukemia. Blood, 2012, 119, 1086-1087.	0.6	16
30	JNK1 and ERK1/2 modulate lymphocyte homeostasis via BIM and DRP1 upon AICD induction. Cell Death and Differentiation, 2020, 27, 2749-2767.	5.0	16
31	Identification of the NUP98-PHF23 fusion gene in pediatric cytogenetically normal acute myeloid leukemia by whole-transcriptome sequencing. Journal of Hematology and Oncology, 2015, 8, 69.	6.9	14
32	Core Binding Factor Acute Myeloid Leukemia In Pediatric Patients Enrolled In The AIEOP AML 2002/01 Trial: The Impact Of Minimal Residual Disease On Patient Outcome. Blood, 2013, 122, 3884-3884.	0.6	14
33	The effect of the cyclin-dependent kinase inhibitor flavopiridol on anaplastic large cell lymphoma cells and relationship with NPM-ALK kinase expression and activity. Haematologica, 2009, 94, 944-955.	1.7	13
34	Whole transcriptome sequencing of a paediatric case of <i>de novo</i> acute myeloid leukaemia with del(5q) reveals <i><scp>RUNX</scp>1</i> â€ <i><scp>USP</scp>42</i> and <i><scp>PRDM</scp>16â€<scp>SKI</scp></i> fusion transcripts. British Journal of Haematology, 2014, 166, 449-452.	1.2	12
35	DNA methyltransferase 3a hot-spot locus is not mutated in pediatric patients affected by acute myeloid or T-cell acute lymphoblastic leukemia: an Italian study. Haematologica, 2011, 96, 1886-1887.	1.7	11
36	Screening of novel genetic aberrations in pediatric acute myeloid leukemia: a report from the AIEOP AML-2002 study group. Blood, 2012, 120, 3860-3862.	0.6	11

#	Article	IF	CITATIONS
37	Targeting BAG-1: A novel strategy to increase drug efficacy in acute myeloid leukemia. Experimental Hematology, 2015, 43, 180-190.e6.	0.2	11
38	A Case of Tâ€eell Acute Lymphoblastic Leukemia Relapsed As Myeloid Acute Leukemia. Pediatric Blood and Cancer, 2016, 63, 1660-1663.	0.8	10
39	<scp>CD56</scp> , <scp>HLAâ€DR,</scp> and <scp>CD45</scp> recognize a subtype of childhood <scp>AML</scp> harboring <scp>CBFA2T3â€GLIS2</scp> fusion transcript. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2021, 99, 844-850.	1.1	10
40	A threeâ€mi <scp>RNA</scp> â€based expression signature at diagnosis can predict occurrence of relapse in children with t(8;21) <i><scp>RUNX</scp>1</i> é <i><scp>RUNX</scp>1T1</i> acute myeloid leukaemia. British Journal of Haematology, 2018, 183, 298-301.	1.2	8
41	Thioridazine requires calcium influx to induce MLL-AF6–rearranged AML cell death. Blood Advances, 2020, 4, 4417-4429.	2.5	8
42	Two consecutive immunophenotypic switches in a child with MLL-rearranged acute lymphoblastic leukemia. Haematologica, 2006, 91, ECR09.	1.7	8
43	Low Prevalence of IDH1 gene Mutation In Childhood AML In Italy Blood, 2010, 116, 1678-1678.	0.6	7
44	ICER Evokes Dusp1-p38 Pathway Enhancing Chemotherapy Sensitivity in Myeloid Leukemia. Clinical Cancer Research, 2011, 17, 742-752.	3.2	6
45	The long non-coding RNA CDK6-AS1 overexpression impacts on acute myeloid leukemia differentiation and mitochondrial dynamics. IScience, 2021, 24, 103350.	1.9	6
46	Novel Compounds Synergize With Venetoclax to Target KMT2A-Rearranged Pediatric Acute Myeloid Leukemia. Frontiers in Pharmacology, 2021, 12, 820191.	1.6	5
47	The altered transcriptome of pediatric myelodysplastic syndrome revealed by RNA sequencing. Journal of Hematology and Oncology, 2020, 13, 135.	6.9	4
48	BAG1 downâ€regulation increases chemoâ€sensitivity of acute lymphoblastic leukaemia cells. Journal of Cellular and Molecular Medicine, 2021, 25, 9060-9065.	1.6	3
49	NUP98 Fusion Proteins Are Recurrent Aberrancies in Childhood Acute Myeloid Leukemia: A Report from the AIEOP AML-2001-02 Study Group. Blood, 2014, 124, 1025-1025.	0.6	3
50	Clonal Evolution and Lack of BCR-ABL1 Mutations in Pediatric Ph+ ALL Patients Resistant/Refractory to Imatinib Treatment. Blood, 2015, 126, 2622-2622.	0.6	3
51	Acute Myeloid Leukemia (AML) in a 3D Bone Marrow Niche Showed High Performance for in Vitro and In Vivo Drug Screenings. Blood, 2019, 134, 544-544.	0.6	2
52	NPM1 Mutational Status Underlines Different Biological Features in Pediatric AML. Cancers, 2021, 13, 3457.	1.7	1
53	Integrative Analysis of Pediatric Acute Leukemia Identifies Immature Subtypes That Span a T Lineage and Myeloid Continuum with Distinct Prognoses. Blood, 2019, 134, 918-918.	0.6	1
54	Impact of Minimal Residual Disease (MRD) Assessed before Transplantation on the Outcome of Children with Acute Myeloid Leukemia Given an Allograft: A Retrospective Study By the I-BFM Study Group. Blood, 2020, 136, 38-39.	0.6	1

#	Article	IF	CITATIONS
55	Prognostic Relevance of Recurrent Genetic Aberrations in Pediatric Acute Megakaryoblastic Leukemia. Blood, 2015, 126, 2598-2598.	0.6	1
56	Dna Methylation Is Linked to a Specific Cell-Adhesion Program in Relapsed Pediatric t(8;21)(q22;q22)RUNX1-RUNX1T1 Patients. Blood, 2016, 128, 1524-1524.	0.6	1
57	MiR-34b Promoter Methylation and Regulation of CREB Expression In Myeloid Transformation. Blood, 2010, 116, 538-538.	0.6	1
58	Molecular Measurable Residual Disease Assessment before Hematopoietic Stem Cell Transplantation in Pediatric Acute Myeloid Leukemia Patients: A Retrospective Study by the I-BFM Study Group. Biomedicines, 2022, 10, 1530.	1.4	1
59	Editorial: New Perspectives on Pediatric Acute Leukemia. Frontiers in Pediatrics, 2020, 8, 618426.	0.9	O
60	Pumpless Microfluidic System for Bone Marrow Niche-on-a-Chip in vitro Modelling and Multiphoton Imaging in Leukemia. Biophysical Journal, 2020, 118, 463a.	0.2	0
61	BAG1 Overexpression Restrains the Anti-Apoptotic BCL2, MCL1 and HSP70 Proteins in Acute Myeloid Leukemia Blood, 2012, 120, 2492-2492.	0.6	0
62	Favourable Outcome in Infants with Acute Myeloid Leukemia Treated with the AIEOP AML 2002/01 Protocol. Blood, 2012, 120, 3585-3585.	0.6	0
63	NOVEL Recurrent Genetic Aberrations in Pediatric AML: An AIEOP AML-2002 Study Group Blood, 2012, 120, 2494-2494.	0.6	0
64	The cAMP Response Element Binding Protein (CREB) Overexpression Induces Myeloid Transformation in Zebrafish. Blood, 2012, 120, 4727-4727.	0.6	0
65	Characterization of lincRNA BALIR-6 in MLL rearranged B-lymphoblastic leukemia. Blood, 2013, 122, 3730-3730.	0.6	0
66	ZNF521 Is a Zinc Finger Protein That Prevents Differentiation Of Human MLL-AF9-Positive Myeloid Leukemic Cells. Blood, 2013, 122, 1255-1255.	0.6	0
67	Core Binding Factor Acute Myeloid Leukemia In Pediatric Patients Of The AIEOP AML 2002/01 Trial: Screening and Prognostic Impact Of cKIT Mutations. Blood, 2013, 122, 2655-2655.	0.6	0
68	LincRNA Expression Discriminates Cytogenetic Subtypes In B-Lymphoblastic Leukemia and Plays a Functional Role In Leukemia Cell Survival. Blood, 2013, 122, 2570-2570.	0.6	0
69	Abstract LB-211: NUP98-PHF23 is a novel fusion gene in pediatric cytogenetically normal acute myeloid leukemia., 2015,,.		0
70	Clinical and Biological Characterization of Children with FLT3ITD Mutated Acute Myeloid Leukemia (AML): A Report from the AIEOP AML-2002 Study Group. Blood, 2015, 126, 3845-3845.	0.6	0
71	Characterizing the Function of an RNA Binding Protein, IGF2BP3, in Hematopoiesis. Blood, 2015, 126, 3664-3664.	0.6	0
72	New Therapeutic Opportunities for Pediatric Patients with t(6;11)-Rearranged Acute Myeloid Leukemia. Blood, 2016, 128, 749-749.	0.6	0

#	Article	IF	CITATIONS
73	Molecular Characterization of Long Non-Coding RNA CASC15 in Leukemogenesis. Blood, 2016, 128, 5103-5103.	0.6	0
74	The Long Noncoding RNA BALR2 Controls Novel Transcriptional Circuits Involved in Chemotherapy Sensitivity of Pediatric Acute Myeloid Leukemia (AML) Blasts. Blood, 2019, 134, 2734-2734.	0.6	0
75	Abstract 3107: A scientific task force to generate proof-of-concept data packages for clinical trials in pediatric cancers: The hepatoblastoma example. , 2019, , .		O
76	Extranodal Biphenotypic Non-Hodgkin Lymphoma of the Popliteal Cavity: A Case Report and Review of Literature. Diagnostics, 2022, 12, 1649.	1.3	O